期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 65, 期 -, 页码 382-391出版社
ELSEVIER
DOI: 10.1016/j.intimp.2018.10.030
关键词
Cathelicidin-BF; Pseudomonas aeruginosa; Pneumonia; NETosis; Autophagy
资金
- National Natural Science Foundation of China [81503117, 81460322]
- CAMS Initiative for Innovative Medicine [2017-I2M-3-022]
- Foundation for Studying Abroad from the State Administration of Foreign Experts Affairs China [201808110121]
- China Scholarship Council [201808110121]
- Fundamental Research Funds for the Central Universities of China [2016ZX350073, 2018018001, 3332013084]
- Opening Foundation of the Key Laboratory of Bioactive Peptides of Yunnan Province [AMHD-2017-1]
Although the antimicrobial peptide cathelicidin-BF shows minimal cytotoxicity in mammalian cells and has excellent direct killing effects on multidrug-resistant clinical pathogens such as Pseudomonas aeruginosa, its clinical application is precluded by its high sensitivity to serum proteases. Here, we demonstrate that intravenous administration of cathelicidin-BF after P. aeruginosa infection did not increase the survival rate of mice with acute pneumonia but that pretreatment with cathelicidin-BF ameliorated pneumonia by effectively activating innate immunity. Enhanced neutrophil extracellular trap (NET) activation and release (NETosis) are key processes for capturing and killing bacteria, concomitantly enhanced macrophage clearance activity, including phagocytosis and autophagy, may eliminate NETs early enough to prevent severe tissue damage. Our study not only suggests a possible approach for applying cathelicidin-BF in vivo but also provides a possible defense strategy against multidrug-resistant pathogens, i.e., efficiently activation of innate immunity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据